Science News

... from universities, journals, and other research organizations

Renewed Hope For Parkinson's Patients

July 3, 2005 — Analysis of the brain of a patient suffering from Parkinson's Disease has shown that the experimental treatment he received caused regrowth of the nerve fibres that are lost in this disease. The findings are reported in the July issue of Nature Medicine.


Share This:

This is the first time that any treatment has been shown to reverse the loss of nerve fibres in Parkinson's Disease.

The 62-year-old man was one of five patients in a pilot study carried out by Mr Steven Gill at Frenchay Hospital in Bristol, UK. In this study, an experimental drug (GDNF) was pumped through a fine catheter into a damaged part of the brain. Within a couple of months, patients were noticing dramatic improvements in their ability to move, and these continued over almost four years of treatment. Even after ceasing medication, the patients' improvement has been maintained.

After the death of the 62-year-old patient from a heart attack, Professor Seth Love from Bristol University was able to examine his brain. Because the GDNF had been infused into one side of the brain only, the effects of the treatment could be assessed by comparing the two sides.

In Parkinson's Disease, nerves containing the chemical messenger dopamine are lost from a region of the brain region known as the putamen, leading to tremors and other motor abnormalities characteristic of the disease.

Professor Love found that dopamine-containing nerve fibres had sprouted back in the putamen. He said: "This is the first neuropathological evidence that infusion of GDNF in humans causes sprouting of dopamine fibres, in association with a reduction in the severity of Parkinson's Disease." The findings may revitalise interest in GDNF administration as a potential therapy for this degenerative condition, providing renewed hope for patients disappointed by the recent withdrawal of this drug due to concerns about its safety.

GDNF, which stands for glial cell line-derived neurotrophic factor, is a natural growth agent needed by brain cells to produce dopamine, which transmits impulses between certain nerve cells including those that regulate movement. A reduced concentration of dopamine in the brain is associated with Parkinson's Disease.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by University of Bristol, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,088

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Glasses Help Parkinson's Patients

Working with electrical engineers, a podiatrist has designed a pair of glasses that helps people with Parkinson's to walk with less difficulty.. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: